Related references
Note: Only part of the references are listed.WNT1 Mutations in Families Affected by Moderately Severe and Progressive Recessive Osteogenesis Imperfecta
Shawna M. Pyott et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2013)
Mutations in WNT1 Cause Different Forms of Bone Fragility
Katharina Keupp et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2013)
Standardized Nomenclature, Symbols, and Units for Bone Histomorphometry: A 2012 Update of the Report of the ASBMR Histomorphometry Nomenclature Committee
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
An RNA-seq Protocol to Identify mRNA Expression Changes in Mouse Diaphyseal Bone: Applications in Mice with Bone Property Altering Lrp5 Mutations
Ugur M. Ayturk et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
WNT signaling in bone homeostasis and disease: from human mutations to treatments
Roland Baron et al.
NATURE MEDICINE (2013)
WNT1 Mutations in Early-Onset Osteoporosis and Osteogenesis Imperfecta
Christine M. Laine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Lrp5 and Lrp6 Exert Overlapping Functions in Osteoblasts during Postnatal Bone Acquisition
Ryan C. Riddle et al.
PLOS ONE (2013)
Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
Maarten van Dinther et al.
PLOS ONE (2013)
LRP5 and LRP6 in development and disease
Danese M. Joiner et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Genetic association study of WNT10B polymorphisms with BMD and adiposity parameters in Danish and Belgian males
Jasmijn K. Van Camp et al.
ENDOCRINE (2013)
The sclerostin-bone protein interactome
Hemamalini Devarajan-Ketha et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity
Johanna Korvala et al.
BMC MEDICAL GENETICS (2012)
Characterization of the Interaction of Sclerostin with the Low Density Lipoprotein Receptor-related Protein (LRP) Family of Wnt Co-receptors
Gill Holdsworth et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
Austin Gurney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Sclerostin: Therapeutic Horizons Based Upon Its Actions
Aline G. Costa et al.
CURRENT OSTEOPOROSIS REPORTS (2012)
Structural Basis of Wnt Signaling Inhibition by Dickkopf Binding to LRP5/6
Victoria E. Ahn et al.
DEVELOPMENTAL CELL (2011)
Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia
Su Jin Kim et al.
HUMAN GENETICS (2011)
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Olivier Leupin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Teriparatide Increases Bone Mineral Density in a Man With Osteoporosis Pseudoglioma
Henrique Pierotti Arantes et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Lrp5 functions in bone to regulate bone mass
Yajun Cui et al.
NATURE MEDICINE (2011)
Crystal structures of the extracellular domain of LRP6 and its complex with DKK1
Zhihong Cheng et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Wnt Antagonists Bind through a Short Peptide to the First β-Propeller Domain of LRP5/6
Eric Bourhis et al.
STRUCTURE (2011)
Sclerostin-erbB-3 interactions: Modulation of erbB-3 activity by sclerostin
Theodore A. Craig et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Genetic evidence that SOST inhibits WNT signaling in the limb
Nicole M. Collette et al.
DEVELOPMENTAL BIOLOGY (2010)
Parathyroid Hormone (PTH)-Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice
Ina Kramer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis
Ina Kramer et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Wnt Isoform-Specific Interactions with Coreceptor Specify Inhibition or Potentiation of Signaling by LRP6 Antibodies
Yan Gong et al.
PLOS ONE (2010)
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies
Seth A. Ettenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The role of Dickkopf-1 in bone development, homeostasis, and disease
Joseph J. Pinzone et al.
BLOOD (2009)
Novel Wnt antagonists target porcupine and Axin
Jing-Ruey J. Yeh et al.
NATURE CHEMICAL BIOLOGY (2009)
Osteoporosis-pseudoglioma syndrome: Description of 9 new cases and beneficial response to bisphosphonates
Elizabeth A. Streeten et al.
BONE (2008)
The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations
Wendy Balemans et al.
CALCIFIED TISSUE INTERNATIONAL (2008)
Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum
Vijay K. Yadav et al.
CELL (2008)
Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd
Takuo Kubota et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes
Anne-Marie Sims et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
LRP6 mutation in a family with early coronary disease and metabolic risk factors
Arya Mani et al.
SCIENCE (2007)
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation
Rutger L. van Bezooijen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST
Mikhail V. Semenov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity
Debra L. Ellies et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Wnt/β-catenin signaling is a normal physiological response to mechanical loading in bone
John A. Robinson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
SOST is a target gene for PTH in bone
H Keller et al.
BONE (2005)
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor
M Semënov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
GG Loots et al.
GENOME RESEARCH (2005)
Essential role of β-catenin in postnatal bone acquisition
SL Holmen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling
M Ai et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling
XF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes
TP Hill et al.
DEVELOPMENTAL CELL (2005)
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation
DA Glass et al.
DEVELOPMENTAL CELL (2005)
Regulation of osteoblastogenesis and bone mass by Wnt10b
CN Bennett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6
SL Holmen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with mesd
YH Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity
N Kusu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
High bone mass in mice expressing a mutant LRP5 gene
P Babij et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population
K Staehling-Hampton et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
High bone density due to a mutation in LDL-receptor-related protein 5
LM Boyden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor
M Kato et al.
JOURNAL OF CELL BIOLOGY (2002)
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
W Balemans et al.
JOURNAL OF MEDICAL GENETICS (2002)
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait
RD Little et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development
YQ Gong et al.
CELL (2001)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
ME Brunkow et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
W Balemans et al.
HUMAN MOLECULAR GENETICS (2001)
Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34)
M Kneissel et al.
BONE (2001)
Share Paper
